Advertisement

Picture [iito] Made Without Love 650x80px
Document › Details

Versameb AG. (12/18/18). "Press Release: Versameb Ltd Raises CHF 5.3 Million for the Development of mRNA Therapies in Regenerative Medicine". Basel.

Organisation Organisation Versameb AG
Products Product mRNA-based drug
  Product 2 venture capital
Index term Index term Versameb–SEVERAL: investment, 201812 colsing of seed B financing round brining total capital raised to date to CHF5.3m
Persons Person Metzger, Friedrich (Versameb 201910 CEO)
  Person 2 Meier, Roger (Versameb 201812 Board Chairman)
     


Versameb Ltd, a Swiss biopharmaceutical company, announced today the successful closing of a Seed B financing round, bringing the total capital raised to date to CHF 5.3 millions. Versameb Ltd is developing a technology platform for transformative therapies, focusing on regenerative medicine through the local application of messenger ribonucleic acid (mRNA).

“We are very pleased and grateful that our company is enjoying strong support from Swiss and international private investors with both scientific and financial background” commented Prof. Dr. Friedrich Metzger, Versameb’s CEO. He added: “Thanks to our team, we were able to kick-start our operations rapidly and create substantial value in a short period of time. Our technology has the potential to address a broad variety of currently unmet medical needs. I look forward to an exciting discovery and development journey.”

The proceeds will fund the extension of the platform technology, starting of pre-IND activities with the lead program and preclinical activities for additional regenerative medicine indications, and will secure the company’s corporate needs for organizational growth.


About Versameb Ltd

Versameb Ltd. a preclinical-stage biopharmaceutical company located in Basel, Switzerland. It became operational at the beginning of 2018 and employs a team of experts in drug discovery, research and development and complemented by life sciences venture professionals. Versameb’s proprietary platform technology optimizes the use of functional mRNA for the local application in various disease contexts. The current focus is on regenerative medicine, but the approach offers a broad array for the development of potential therapeutic options.


Contact for Media Enquiries

Roger Meier, Chairman of the Board

Peter Merian-Strasse 45 | CH-4052 Basel
+41 61 378 87 03 | +41 79 434 52 40
roger.meier@versameb.com

   
Record changed: 2020-05-28

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Versameb AG


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top